Device/Diagnostics Quarterly Deal Statistics, Q1 2015
Device financing rose slightly to $934 million in Q1, while acquisition value was down to just over $4 billion. Diagnostics fundraising dropped significantly to $597 million; M&A activity was dominated by NGS and Roche's transaction with Foundation Medicine.
You may also be interested in...
Boston Sci Ups Urology Focus With $1.6 Billion AMS Deal
The firm is expanding its leadership position in the urology space with its acquisition of American Medical Systems's men's health and prostate health units.
Cardinal Health Builds On Generic Device Strategy With Cordis Deal
The $1.99 billion Cordis acquisition is a major step in Cardinal's strategy to build its offerings of devices with a high physician preference but for which there is limited clinical differentiation and inefficient supply chains.
Roche Gains Majority Stake In Foundation Medicine With R&D, Commercial Partnership
Roche is investing up to $1.18 billion in the genomic analysis firm, inking a partnership focused on companion diagnostics, cancer drug development and expanded marketing of Foundation's novel sequencing-based platform.